Health Affairs' Jeff Byers welcomes Farzad Mostashari, founder & CEO of Aledade and the former National Coordinator for ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

To address the demand-side of this fight, a prevention and treatment-based approach is necessary, as state officials can ...

Massachusetts’ new health care reform expands the authority of the state to intervene prior to significant changes to the ...

During the COVID-19 pandemic, suppression of scientific debate and the marginalization of dissenting voices weakened public ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Eric Topol, Executive Vice President of Scripps Research, on his new ...

Unless Congress acts to renew them by the end of this year, enhanced premium subsidies for the Affordable Care Act’s ...

As health scholars at the American Enterprise Institute, the Brookings Institution, and the Bipartisan Policy Center, we ...

Early detection of rare but treatable diseases has long been one of public health’s quiet triumphs, sparing thousands of ...

By May 5, 2025, the Trump administration will file its first brief in Missouri v. Food and Drug Administration, staking out a ...

This article highlights a striking example of pointless complexity in the US health care system: the 24 (or more) separate ...

Loneliness and social isolation have long been linked to a range of health conditions; social prescribing represents a new kind of treatment.